Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation

Journal of the American College of Cardiology

Volumn 72, Issue 3, 2018, Pages 255-267

  Kent, Anthony P ^a   Brueckmann, Martina ^b,c   Fraessdorf, Mandy ^b   Connolly, Stuart J ^d   Yusuf, Salim ^d   Eikelboom, John W ^d   Oldgren, Jonas ^e   Reilly, Paul A ^f   Wallentin, Lars ^e   Ezekowitz, Michael D ^g  

^a BRIDGEPORT HOSPITAL   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HAMILTON HEALTH SCIENCES   (Canada)

^e UPPSALA UNIVERSITY   (Sweden)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

anticoagulation; atrial fibrillation; bleeding; NSAID; stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN ETEXILATE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN; DABIGATRAN;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; THROMBOSIS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPLICATION; DRUG INTERACTION; HOSPITALIZATION; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ATRIAL FIBRILLATION; DABIGATRAN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 85049308797     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.04.063     Document Type: Article

References (39)

1. Rouzer, C.A., Marnett, L.J., Cyclooxygenases: structural and functional insights. J Lipid Res 50 Suppl (2009), S29–S34.
2. Solomon, S.D., McMurray, J.J., Pfeffer, M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005), 1071–1080.
3. Nissen, S.E., Yeomans, N.D., Solomon, D.H., et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 375 (2016), 2519–2529.
4. Solomon, D.H., Husni, M.E., Libby, P.A., et al. The risk of major NSAID toxicity with celecoxib, ibuprofen or naproxen: a secondary analysis of the PRECISION randomized controlled clinical trial. Am J Med 130 (2017), 1415–1422.e4.
5. Chang, C.H., Shau, W.Y., Kuo, C.W., Chen, S.T., Lai, M.S., Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case crossover study. Stroke 41 (2010), 1884–1890.
6. Fosbøl, E.L., Olsen, A.M., Olesen, J.B., et al. Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety. Int J Stroke 9 (2014), 943–945.
7. Lamberts, M., Lip, G.Y., Hansen, M.L., et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med 161 (2014), 690–698.
8. Schjerning, O.A.M., Gislason, G.H., McGettigan, P., et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA 313 (2015), 805–814.
9. Harirforoosh, S., Jamali, F., Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 8 (2009), 669–681.
10. Arfè, A., Scotti, L., Varas-Lorenzo, C., et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ, 354, 2016, i4857.
11. Adams, R.J., Appleton, S.L., Gill, T.K., Taylor, A.W., Wilson, D.H., Hill, C.L., Cause for concern in the use of non-steroidal anti-inflammatory medications in the community–a population-based study. BMC Fam Pract, 12, 2011, 70.
12. Ilomäki, J., Helin-Salmivaara, A., Huupponen, R., Rikala, M., Kirkpatrick, C.M., Korhonen, M.J., Analgesic use before and after oral anticoagulant initiation–a population-based study in Finland. Eur J Clin Pharmacol 71 (2015), 723–732.
13. Davidson, B.L., Verheijen, S., Lensing, A.W., et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern Med 174 (2014), 947–953.
14. U.S. Department of Health and Human Services. CDC Vital Signs: Arthritis in America. 2017, Centers for Disease Control and Prevention, Atlanta, GA Available at: www.cdc.gov/vitalsigns/arthritis Accessed March 11, 2017.
15. Lip, G.Y., Nonsteroidal anti-inflammatory drugs and bleeding risk in anticoagulated patients with atrial fibrillation. Expert Rev Cardiovasc Ther 13 (2015), 963–965.
16. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151 erratum, N Engl J Med 2010;363:1877.
17. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
18. Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
19. Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
20. Friedman, R.J., Kurth, A., Clemens, A., Noack, H., Eriksson, B.I., Caprini, J.A., Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding. Thromb Haemost 108 (2012), 183–190.
21. Schulman S, Eriksson H, Goldhaber SZ, et al. Influence of concomitant NSAID or ASA on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II. Poster presented at: 55th Annual Meeting of the American Society of Hematology. New Orleans, LA; December 7−10, 2013.
22. EINSTEIN Investigators, Bauersachs, R., Berkowitz, S.D., Brenner, B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
23. EINSTEIN–PE Investigators, Büller, H.R., Prins, M.H., Lensin, A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366 (2012), 1287–1297.
24. Ezekowitz, M.D., Connolly, S., Parekh, A., et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157 (2009), 805–810 810.e1-2.
25. Dans, A.L., Connolly, S.J., Wallentin, L., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 127 (2013), 634–640.
26. Gislason, G.H., Torp-Pedersen, C., NSAIDs and the failing heart. BMJ, 354, 2016, i5163.
27. Brophy, J.M., Lévesque, L.E., Zhang, B., The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 93 (2007), 189–194.
28. Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e322.
29. Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129 (2014), 837–847.
30. Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health. NSDUH Data Review. Available at: https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm#topofpage. Accessed June 5, 2018.
31. Murthy, V.H., Ending the opioid epidemic - a call to action. N Engl J Med 375 (2016), 2413–2415.
32. Antman, E.M., Bennett, J.S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K.A., Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007), 1634–1642.
33. Gislason, G.H., Jacobsen, S., Rasmussen, J.N., et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 113 (2006), 2906–2913.
34. Schjerning Olsen, A.M., Fosbøl, E.L., Lindhardsen, J., et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123 (2011), 2226–2235.
35. McGettigan, P., Henry, D., Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med, 8, 2011, e1001098.
36. Felson, D.T., Safety of nonsteroidal antiinflammatory drugs. N Engl J Med 375 (2016), 2595–2596.
37. Grosser, T., Ricciotti, E., FitzGerald, G.A., The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 38 (2017), 733–748.
38. Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382 (2013), 769–779.
39. Bally, M., Dendukuri, N., Rich, B., et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ, 357, 2017, j1909.